CAR T-cell Therapy CT103A Produces Durable Responses in Relapsed/Refractory Multiple Myeloma
August 3rd 2022
The fully human BCMA-directed CAR T-cell therapy, CT103A, demonstrated deepening efficacy with an acceptable toxicity profile in patients with relapsed or refractory multiple myeloma, according to updated data from the phase 1/2 FUMANBA-1 trial.